Organizing race : paths toward the re-biologization of race in modern biomedical research, practice, and product development -- The birth of BiDil : how a drug becomes "ethnic" -- Statistical mischief and racial frames for drug development and marketing -- Capitalizing (on) race in drug development -- Race-ing patents/patenting race : an emerging political geography of intellectual property in biotechnology -- Not fade away : the persistence of race and the politics of the "meantime" in pharmacogenomics -- From disparity to difference : the politics of racial medicine
Summary
Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was touted as a pathbreaking therapy to treat heart failure in black patients. Kahn reveals that, at the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. He examines the legal and calls for a more reasoned approach to using race in biomedical research and practice
Bibliography
Includes bibliographical references (pages 247-301) and index
